Jaguar Health, Inc. (NASDAQ:JAGX) | WebDisclosure

Basculer en Français

9480	Companies
185564	Keywords
117971	Articles
99400	Press releases

Home
Companies
Jaguar Health, Inc.

PRESS RELEASE

published on 04/18/2024 at 14:30, 1 year 7 months ago

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care
Catherine Miller Collis joins Jaguar Health, facilitating in-license agreement for FDA-approved Gelclair® for oral mucositis management. Collis brings 25 years of biopharmaceutical experience to Senior VP role at Jaguar. Gelclair provides pain relief for cancer patients' supportive care needs

Cancer Treatment Jaguar Health Gelclair Oral Mucositis Catherine Miller Collis
BRIEF

published on 04/16/2024 at 14:35, 1 year 7 months ago

Jaguar Health Secures Exclusive License for FDA-Approved Oral Mucositis Gel, Targets Q3 2024 Commercial Launch

FDA Approval Jaguar Health Gelclair Oral Mucositis Cancer Supportive Care
BRIEF

published on 04/16/2024 at 14:35, 1 year 7 months ago

Jaguar Health obtient une licence exclusive pour le gel contre la mucite buccale approuvé par la FDA et vise un lancement commercial au troisième trimestre 2024

Approbation De La FDA Santé Jaguar Gelclair Mucite Buccale Soins De Soutien Contre Le Cancer
PRESS RELEASE

published on 04/16/2024 at 14:30, 1 year 7 months ago

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care
Jaguar Health, Inc. announces commercial launch in Q3 2024 for Gelclair® for cancer supportive care. Gelclair is an FDA-approved oral mucositis prescription product for pain management in oncology

Jaguar Health Inc. Commercial Launch Gelclair Oral Mucositis Prescription Product
BRIEF

published on 04/09/2024 at 22:20, 1 year 7 months ago

Jaguar Health Reports Successful Stockholder Meeting and Progress on Clinical Trial

Jaguar Health Nasdaq Compliance Cancer Therapy Stockholder Meeting Crofelemer Clinical Trial
BRIEF

published on 04/09/2024 at 22:20, 1 year 7 months ago

Jaguar Health annonce une assemblée d’actionnaires réussie et des progrès dans les essais cliniques

Assemblée Générale Santé Jaguar Thérapie Contre Le Cancer Conformité Au Nasdaq Essai Clinique Crofelemer
PRESS RELEASE

published on 04/09/2024 at 22:15, 1 year 7 months ago

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders
Jaguar Health, Inc. announces decision not to implement a reverse split at this time. Top line results for phase 3 OnTarget trial of crofelemer pending. Stockholders approve proposals at Special Meeting

Crofelemer Stockholders Meeting Jaguar Health Reverse Split Phase 3 Trial
BRIEF

published on 04/08/2024 at 14:35, 1 year 7 months ago

Jaguar Health Granted Extension to Regain Nasdaq Compliance, Announces OnTarget Trial Results Soon

Crofelemer Jaguar Health Nasdaq Compliance Cancer Therapy OnTarget Trial
BRIEF

published on 04/08/2024 at 14:35, 1 year 7 months ago

Jaguar Health obtient une prolongation pour rétablir la conformité au Nasdaq et annonce bientôt les résultats de l'essai OnTarget

Crofelemer Santé Jaguar Thérapie Contre Le Cancer Conformité Au Nasdaq Essai OnTarget
PRESS RELEASE

published on 04/08/2024 at 14:30, 1 year 7 months ago

Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement
Jaguar Health, Inc. announces extended grace period from Nasdaq for bid price compliance. Top line results awaited for crofelemer's cancer therapy-related diarrhea prevention trial

Crofelemer Nasdaq Jaguar Health Cancer Therapy Grace Period

Accesswire

Published on 12/06/2025 at 02:00, 9 hours 34 minutes ago

Northern Dynasty Provides Update on Board Search and Audit & Risk Committee Composition
Published on 12/06/2025 at 01:15, 10 hours 19 minutes ago

Prospect Ridge Announces Closing of Flow-Through Unit Private Placement
Published on 12/06/2025 at 00:25, 11 hours 9 minutes ago

GMV Minerals Announces Non-Brokered Private Placement Pursuant to the Listed Issuer Financing Exemption
Published on 12/06/2025 at 00:00, 11 hours 34 minutes ago

Bird River Announces Closing of $0.10 Common Share Financing
Published on 12/05/2025 at 23:30, 12 hours 4 minutes ago

55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 22:15, 13 hours 19 minutes ago

CPI PROPERTY GROUP - Changes in Shareholding and Board of Directors
Published on 12/05/2025 at 22:12, 13 hours 22 minutes ago

EQS-Adhoc: CPI PROPERTY GROUP - Change to Distribution Policy
Published on 12/05/2025 at 18:58, 16 hours 36 minutes ago

EQS-Adhoc: HORNBACH Holding AG & Co. KGaA: Reduced earnings in Q3 2025/26 – Guidance for adjusted EBIT at previous year’s level still valid
Published on 12/05/2025 at 18:26, 17 hours 8 minutes ago

POS-Transaction in Own Shares
Published on 12/05/2025 at 18:15, 17 hours 19 minutes ago

Completion of merger to form Helvetia Baloise Holding Ltd

Les Echos

Published on 12/05/2025 at 23:00, 12 hours 34 minutes ago

ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 12 hours 34 minutes ago

ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 12/05/2025 at 23:00, 12 hours 34 minutes ago

ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 23:00, 12 hours 34 minutes ago

ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES NOVEMBRE 2025
Published on 12/05/2025 at 17:18, 18 hours 16 minutes ago

La vidéo de la réunion de présentation des résultats 2024-2025 du 5 décembre 2025 est disponible

View all LES ECHOS COMFI WIRE